木瓜直播

Seeing whether it can predict response to antifibrotic therapies is next step

Diagnosis coupled with financial burden makes for a difficult situation, but help is out there

"Clear trend" for improved progression-free survival in subgroup with brain metastases as well

HR-positive breast cancer patients with ER mutations doubled their median PFS

PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria

Halle Moore, MD, discusses the data and clinical implications

Evidence isn't great to inform a sequencing choice, says Megan Kruse, MD

Megan Kruse, MD, wonders where it leaves AKT inhibitors in metastatic breast cancer

Hannah Linden, MD, discusses the encouraging results from the AMEERA-1 trial